Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02132169 · ClinicalTrials.gov registry record · Phase 3
A Multi-Center Study Evaluating the Safety of AC-170 0.24%
A Phase 3 study, sponsored by Aciex Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 512
- Enrollment target
NCT02132169 is a Phase 3 study that has completed, run by Aciex Therapeutics. The registered enrollment target is 512 participants.
The verdict
NCT02132169, a Phase 3 study, has completed, sponsored by Aciex Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 512 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of AC-170 0.24% used twice daily in Healthy Adult Subjects and in Pediatric subjects with a history or family history of atopic disease (including allergic conjunctivitis).
Interventions
- DRUG AC-170 0%
- DRUG Drug: AC-170 0.24%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 512 participants |
| Start Date | 2014-05 |
| Est. Completion | 2014-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02132169
The ClinicalTrials.gov registry entry for NCT02132169 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 512 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aciex Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AC-170 0% is the first listed.
NCT02132169 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02132169 about?
NCT02132169 is a clinical study titled "A Multi-Center Study Evaluating the Safety of AC-170 0.24%". The purpose of this study is to evaluate the safety of AC-170 0.24% used twice daily in Healthy Adult Subjects and in Pediatric subjects with a history or family history of atopic disease (including allergic conjunctivitis).
What is the current status of trial NCT02132169?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 512 participants. The study started on 2014-05. Estimated completion is 2014-10.
What interventions are being tested in trial NCT02132169?
The interventions under investigation include: AC-170 0% (DRUG), Drug: AC-170 0.24% (DRUG).
Who is sponsoring clinical trial NCT02132169?
This trial is sponsored by Aciex Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.